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ABSTRACT

Background: The increase in medication use and expansion of the pharmaceutical industry has led to an increase in hazards,
errors and adverse events associated with medication use. In Lebanon, medication safety reporting by pharmacists is lacking
due to the absence of an official reporting system.
Objective: The objective of the Order of Pharmacists of Lebanon (OPL) was to engage pharmacists in reporting the adverse
drug reactions by creating an efficient tool for this purpose.
Methods: The scientific committee at the OPL worked on designing a reporting tool for adverse drug reactions (ADRs).
Results: An electronic platform was created, and several training sessions were conducted for professionals who would be
involved in helping community or hospital pharmacists in launching the platform. The form was tuned based on the findings
of the Community pharmacists, hospital pharmacists and the general population questionnaires about medication safety
culture, to fit the needs of the practice and to be comprehensive and aligned with international validated standards.
Conclusion: Pilot testing is ongoing and regular continuing education sessions and sensitization campaigns are planned, in
parallel to the official launching of the project in collaboration with the MOPH. This program has important implications in
terms of public health, since knowledge and attitudes are viewed as potentially modifiable factors and their improvement is
expected to decrease underreporting; the OPL is also hoping to improve the patient safety culture in Lebanon.
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1. INTRODUCTION

Akel et al.

to enhance pharmaceutical care and reduce medication
errors in practice[16].

Adverse drug reactions (ADRs) are inevitable harmful
consequences of pharmacotherapy, and are considered a
leading cause of hospital admissions and deaths[1-3]. ADRs
impact significantly healthcare costs, as well. Voluntary
reporting by health professionals is currently considered
the cornerstone for the detection and management of
ADRs and makes a valuable contribution to the safe use
of medicines. Pharmacovigilance activities are essential
for detecting rare but potentially dangerous ADRs, those
occurring after prolonged exposure, and drug–drug and
drug–disease interactions that may not have been observed
in randomized trials conducted prior to drug licensing[4-8].
ADR reporting systems are managed by national ADR
or pharmacovigilance reporting centers, and differ
internationally[9].

Unfortunately, in Lebanon no ADR reporting system is
established yet as compared to other counties in the MENA
region. This system is extremely important to reduce health
costs, unplanned hospital admissions and mortalities
associated with ADRs. Hence, the Order of Pharmacists
of Lebanon (OPL) took the initiative of developing and
launching an online platform to be integrated in a national
pharmacovigilance program.
2. METHODS
2.1. The Order of Pharmacists Initiative: Procedures and
Steps
The OPL is the official pharmacists’ association in
Lebanon and the legal partner of the Ministry of Public
Health to organize and supervise the pharmacy profession.
It was established by law in 1950. The governing body
of the OPL is elected every 3 years by all registered
pharmacists in Lebanon, i.e., total of 8121 active members
in 2018. Its main goal is to advance pharmacy practice
and support pharmacists. Within the OPL, a nominated
Scientific Committee has the role of an executive authority
to organize educational activities including conferences,
educational sessions and certifications. In 2015, the OPL
Scientific Committee took the decision to implement the
safety culture and take ownership of the ADR reporting
among pharmacists.

Since the early 1960s, many countries have adopted
voluntary ADR reporting schemes. In Australia, New
Zealand, Belgium, France, Germany, Canada, Singapore,
Malaysia, South Africa, the UK and the US, there have
been formal reporting systems developed by which health
professionals and, in some countries, consumers can report
ADRs[10].
In Saudi Arabia, pharmacovigilance is a new concept.
However, there are good initiatives being conducted by
some stakeholders, including the Saudi Food and Drug
Authority (SFDA), some pharmaceutical companies
and hospitals[11]. Nevertheless, some further actions
are suggested such as having a gateway to facilitate the
transmission of ADR reports and to increase the number
and quality of partnerships between all stakeholders[11].

The project consisted of multiple steps including
creating the Medication Safety Subcommittee, designing
the reporting tool and the method of report analysis,
assessing the filed medication safety culture, and organizing
training and continuing education sessions on medication
safety.

On another hand, the Egyptian Drug Authority (EDA)
established the Egyptian Pharmacovigilance Center in
December 2009 (EPVC)[12]. EPVC is taking all appropriate
measures to encourage physicians and other healthcare
professionals to report the suspected adverse reactions to
EPVC and obligate marketing authorization holders to
systematically collect information on risks related to their
medical products and to transmit them to EPVC[12]. EPVC
Provides information to end-users through adverse drug
reaction news bulletins, drug alerts and seminars[12].

2.2. Creating the Medication Safety Subcommittee
A call for volunteer service on the Medication Safety
Subcommittee has been out at the beginning of 2016.
Invited pharmacists were pharmacy practitioners in the
community and hospital settings, academic pharmacists, as
well as pharmacists working in pharmaceutical companies
in regulatory, quality and sales/marketing departments.
The final structure of the subcommittee included a total of
12 pharmacists from several fields of practice, including
academia, regulatory, community and hospital pharmacy
practice and medical department officers. Its set objective
was evaluating a process to create a just safety culture
among pharmacists in Lebanon, and identifying the
required roadmap to report ADEs related to any drug
or product administered to a patient in a community
or hospital setting. Two parallel major endeavors were
planned: medication safety reporting tool implementation
and culture field assessment.

Similar to EPVC, the Jordanian Ministry of Health
established in 2001 the Jordan Pharmacovigilance Center
(JPC) within the drug directorate department which is
responsible for the collection and evaluation of information
on pharmaceutical products marketed in Jordan with
particular reference to adverse reactions[13].
A few years later, in 2008, the UAE launched its
National Pharmacovigilance Program[14]. It joined
the WHO International Drug Monitoring Program in
collaboration with the Uppsala Monitoring Centre in
2013[15]. The Health Authority of Abu Dhabi (HAAD) took
initiatives to encourage pharmacovigilance through greater
provision of drug information, the development of a Unified
Prescription Form, and formalization of a "Generic Policy"

2.3. Designing The Medication Safety Reporting Tool
In order to create a standardized reporting and
assessment system that allows reporting and objective
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evaluation of any reaction based on a reliable and
reproducible measurements of causality, there was a need
to use an adverse reaction reporting form. After reviewing
the causality assessment system proposed by the World
Health Organization Collaborating Centre for International
Drug Monitoring, the Uppsala Monitoring Centre
(WHO-UMC), and the Naranjo Probability Scale[17],
the subcommittee created an online form adapted to the
Lebanese context and needs that handles 4 pillars: patient,
reporter, medication and event details. (Appendix A). A
similar downloadable PDF form was also made available
online for non-members of the OPL and for those who
would like to report anonymously.

or submission date. It allows the transfer of data to a
Microsoft Excel sheet for analysis. The end outcome is to
report to concerned authorities to optimize patient safety.
2.5. Assessing the Field Medication Safety Culture
The medication safety subcommittee designed 3
surveys intended to assess the medication safety knowledge
and practice among community pharmacists, hospital
pharmacists and outpatients before the implementation
of the notification tool. A cross-sectional study was
thus carried out between March and July 2016, using a
proportionate random sample of community and hospital
pharmacies from all districts of Lebanon (Beirut, Mount
Lebanon, North, South and Bekaa). A complete list of
community and hospital pharmacists was provided by
the OPL[18]. All pharmacists were targeted by the survey.
For the outpatients’ survey, in every selected community
pharmacy, 2 randomly selected patients were approached
to fill out their addressed survey.

The form collects information related to: a) Name and
the type of the reporting institution; b) demographics about
the patient and the list of medication and supplements
being taken; c) information about the suspected drug and
the prescriber; d) details about the adverse reaction or
product problem including subjective description, picture
or documents attachments, questions related to Naranjo
Scale (for the popularity and simplicity of the scale among
practitioners), laboratories values results if available,
outcome of the reaction, action taken, current status of the
patient and e) reporter’s contact information and details.

The detailed questionnaire was distributed to community
and hospital pharmacists randomly by interviewers. The
interviewers were well trained before the start of the data
collection process. The interviewers explained the study
objectives to participants; obtained their informed written
consents, and informed them that their participation is
completely voluntary. The questionnaire was mainly selfadministered and was completed by participants within
approximately 15-20 minutes. During the data collection
process, the anonymity of the pharmacists was guaranteed
by putting filled out questionnaires into closed boxes. At
the end of the process, the completed questionnaires were
collected by the interviewers and sent for data entry.

The form was then introduced to the OPL Website (www.
opl.org.lb/medicationsafety) with a login information
section, which provides access to the following sets of
expandable headings: a) information on Adverse Reaction
Reporting, b) a summary of what to report, c) Purpose
and scope, d) confidentiality and protection, e) Instruction
to complete the adverse reaction reporting form and f)
the references used. The user will have to acknowledge
understanding prior to being able to report.

The anonymous questionnaire addressed to pharmacists
was in French or English language. It was composed of
different sections: 1. Socio-demographic and practice
characteristics: age, gender, level of education, location of
the pharmacy, surface of the pharmacy, demographic area,
approximate number of patients per day, years of practice,
working hours per week, position in the pharmacy,); 2.
Questions related to the definition and recognition of ADE
and pharmacovigilance; 3. Questions related to reporting;
4. Questions related to patient safety and response to
mistakes. The questionnaire was translated into French or
English by a translator and then translated back by another
translator to ensure translation accuracy.

The form and its preambles has been placed on the
OPL website in 3 languages: Arabic (native), French, and
English. A manual for filling the form has been created and
uploaded online in the preamble section (http://opl.org.lb/
oplwebguide). Finally, a medication safety email has been
created in case pharmacists had any questions, or problem
to report. (medication.safety@opl.org.lb) (Appendix B)
2.4. Analyzing Reported Submissions
The OPL has also designed an electronic system to
analyze the reported events. This system enables dual
screen viewing of the report by administrators. One
screen will enable reading the submitted report (no edition
allowed), and the other split screen will give access to the
complete Naranjo Scale Electronic Form. This latter will
enable a professional objective evaluation to determine the
likelihood of whether an ADE is actually due to the drug
rather than the result of other factors. Causality is assessed
via a score that leads to classifying the ADE into definite,
probable, possible or doubtful. A follow-up message
appears on the screen of the reporter that the submission
has been evaluated, under progress or completed with
the probability results. Furthermore, the system allows
searching the reporting database by drug, reaction severity,

The patient questionnaire addressed the following
areas: (1) patients’ sociodemographic characteristics and
medical condition; (2) elements of medication knowledge;
and (3) medication-related practices and experience,
directed to depict risk-prone behaviors and interest in
medication use and risks. Throughout the questionnaire,
frequency was measured using a five-point Likert scale
with answer categories ranging from always (5) to never
(0). To assess medication-related knowledge, patients were
asked to cite the name, strength and dosage regimen of each
medication they were taking at the time of the interview,
along with the indication, and any potential ADR they
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know may be caused by these medications. The answers,
provided by each patient, were analyzed according to each
of the following 5 elements: name (brand or generic),
strength, dosage regimen, indication, and potential ADRs
(at least one ADR per drug). For each element, patients’
answers were analyzed as follows: patients who knew the
answer for <50% of their medications scored 0, patients
who knew the answer for ≥50% of their medications, but
not 100% scored 1, and patients who knew the answer
for all of their medications scored 2. An index for total
medication knowledge (additive score) was then created,
with a minimum score of zero and a maximum score of 10
(patients who knew all the answers for all the 5 elements
of their medications). Accordingly, the patient’s ‘‘total
medication knowledge’’ was classified as follows: suboptimal medication knowledge (Index score of 0–7); and
optimal medication knowledge (Index score of 8–10).

Akel et al.

system. Around 84.5% of participants highlighted that
the pharmacist is responsible for ADE reporting in their
respective hospital while 61% said they do not support direct
ADE reporting by the patient. Only 64% were trained to
report ADE. The study highlighted the need of educational
programs to emphasize the role and responsibility of
pharmacists in pharmacovigilance practices, and to raise
awareness toward ADE reporting process. This survey is
submitted for publication[19].
3.4. Outpatients’ survey results:
The study included 921 patients, with around 16%
taking ≥5medications/day. Around 56% of the patients
showed sub-optimal medication knowledge. Patients’
higher educational level, number of chronic diseases, and
patient-physician interaction were mainly associated with
higher medication knowledge. Many patients admitted
not discussing the medications they take each time they
visit their doctors (38.7%), not reading the leaflet of each
medication they take (61.2%), and not asking about the
interactions between the over-the-counter drugs they are
buying and the medications they already take (53.9%).
Higher educational level, younger age, and patientphysician interaction were significantly associated with a
higher interest in medication use and safety. Around 40%
of patients reported experiencing ADE. Female gender
and increased number of medications were significantly
associated with a higher frequency of self-reported ADE.
The study showed suboptimal total medication knowledge
and practices, with a particular deficiency in knowledge
of potential ADEs of their medications. The findings were
published in 2017[20].

As for data management and statistical analysis, data
entry was performed by a pharmacist who was not involved
in the data collection process. Statistical analysis was
performed using SPSS software, version 22. Descriptive
statistics were calculated for all study variables; this
includes the counts and percentages for all variables.
3. RESULTS
3.1. Medication Safety reporting tool
The reporting form developed by the medication safety
sub-committee is the product of the work (Appendix A)
that was based on the findings of previous projects run
by the OPL, the results of which are presented in the next
sections.
3.2. Community Pharmacists’ survey results:

4. ORGANIZING TRAINING AND CONTINUING
EDUCATION SESSIONS ON MEDICATION
SAFETY

The results from surveying 1857 community
pharmacists showed that pharmacists had good knowledge
concerning the concept and purpose of pharmacovigilance
as well as adverse drug reactions and events (how to
report, importance of reporting, definition of an ADE
and pharmacovigilance). The majority of communitypharmacists admitted having a positive attitude towards
their role in adverse drug reaction reporting and this
activity was even seen as one of their core duties. The
questionnaire revealed a lack of practice and training
regarding pharmacovigilance. Nonetheless, the pharmacists
agreed on the role of the OPL and the Ministry of Health in
promoting this practice and helping them be more involved
in reporting ADEs. The pharmacists thought they are
well positioned regarding patient-safety practice in their
pharmacies and the results were not statistically different
between pharmacy employers and employees. This survey
was published in 2017[18].

Prior to launching the online forms, a series of
educational activities were delivered in an intent to increase
the pharmacists’ awareness to medication safety, spread the
safety culture, and arm the attendees with the minimum
medication safety terminologies and background to be able
to support and take part of this initiative. The educational
activities delivered were part of:
4.1. National Pharmacist Day Organized by the OPL
(2016)
A review of the different aforementioned assessment
studies was presented to the attending pharmacists. The
presenters highlighted the suboptimal medication safety
knowledge among community pharmacists, hospital
pharmacists and patients; and emphasized on the need
for patients and healthcare professionals to be vigilant
regarding the potential ADRs of their medications.

3.3. Hospital pharmacists’ survey results:

4.2. Annual OPL Congress (2016)

The results of the hospital pharmacists’ surveys
showed that the majority of respondents (N= 187) do not
have adequate knowledge about the concept and process
of pharmacovigilance and spontaneous ADE reporting

The OPL introduced the Medication Safety Initiative,
and the new “Adverse Reaction Reporting form” in three
different languages (Arabic, English and French). The
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7. LIMITATIONS TO ADR REPORTING

presentation guided the attending pharmacists through the
form, and highlighted the need to report any suspected
adverse event to a drug or product used by their patients[21].

A voluntary reporting system of adverse drug events
is fundamental to drug safety surveillance; it represents
the cornerstone of pharmacovigilance. However, all over
the world, spontaneous reporting system shows several
limitations. In this section we will dive deeper to try to
unveil the various restrictions and reasons behind reporting
issues, taking into account the different stakeholders at play.
Other limitations that may arise are: delays in reporting,
difficulties detecting common ADRs, lack of denominator
data, bias, and quality of reports.

4.3. Continuing Education (CE) Program
Medication safety sessions were organized in all
governorates of Lebanon (North, South, Beirut, Bekaa
and Mount Lebanon) and mandated for all licensed
pharmacists. They mainly focused on the recognition of
medication errors and ADEs, on the different classifications
and reporting systems and on stimulating the attending
pharmacists to report suspected ADEs through the online
form launched by the OPL[22].
4.4. Training/Workshop for pharmacists

7.1. Underreporting in Lebanon
In Lebanon, as in other countries, under-reporting
is expected to be a major issue, hindering proper
pharmacovigilance practices. Pharmacists and physicians
claim that it results from a lack of trust in the effectiveness
of the pharmacovigilance reporting centers, a lack of
awareness about existing reporting systems, and the
absence of a clear legal frame resulting in the worry
of being chased legally, being blamed or having a bad
reputation. That reporting is limited only to the medical or
sales representatives of pharmaceutical companies. They
also mention having other interests than reporting.

The medication safety subcommittee organized a set
of advanced training geared to OPL inspectors to provide
them with the necessary medication safety background
knowledge to support the pharmacists in ADE reporting
during their inspection rounds, and guide them through
the adverse reaction reporting form if needed. The training
focused on the classification, assessment, and reporting of
ADEs and briefly reviewed the causality assessments.
In addition, a full-day workshop was organized at the
OPL premises for a small of volunteer pharmacists willing
to participate in the pilot period that is now ongoing.

Another contributor is the lack of awareness about the
medication safety concept among health professionals
and the general population. All pharmacists may not
consider counseling as an essential duty, but that it is the
physician's role. Patients on the other hand, attribute this
to a lack of awareness about a reporting system, lack of
trust in the medical and official parties, carelessness and
a lack of awareness about the medication safety concept
[Unpublished data]. This data is not different from what
was reported in other countries.

5. PROVIDING INCENTIVES TO MEDICATION
SAFETY CULTURE
The effectiveness of a national surveillance program
is highly dependent on the active participation of health
professionals.
As drug experts, and as part of their professional
responsibility, pharmacists are urged to report ADEs
when suspected. The most significant incentive would
be to optimize patient care, reduce patient suffering, and
save patients’ lives by increasing the body of data and
preventing potentially serious ADEs[23].

7.2. Underreporting in other countries: Physician-related
barriers
In a systematic review[24] conducted by Gonzalez et.al,
authors concluded that under-reporting was associated
with ignorance (only severe ADRs need to be reported)
in 95% of studies; diffidence (fear of appearing ridiculous
for reporting merely suspected ADRs) in 72%; lethargy
(an amalgam of procrastination, lack of interest or time to
find a report card, and other excuses) in 77%; indifference
(the one case that an individual doctor might see could
not contribute to medical knowledge) and insecurity (it is
nearly impossible to determine whether or not a drug is
responsible for a particular adverse reaction) in 67%; and
complacency (only safe drugs are allowed on the market)
in 47% of studies[25].

Other potential incentives that are under consideration
by the OPL include allocating CE credits to the pharmacists
for each submission of a truthful adverse reaction report,
and developing a “good catch” award in recognition of
pharmacists who submit adverse event reports that can lead
to the identification or prevention of serious patient harm.
6. PROSPECTIVE STEPS
Pilot testing is ongoing and regular CE sessions and
sensitization campaigns are planned, in parallel to the
official launching of the project in collaboration with the
MOPH. Once the memorandum of understanding signed
with the MOPH, we will urge pharmacists to start reporting
and the first 20 reports will allow us to connect with
Uppsala Monitoring Centre and collaboration with other
stakeholders will be implemented in an integrated national
pharmacovigilance system.

Another study conducted by Figueiras et. al [25]
with the objectives of identifying 1) the practitioner's
demographic and professional characteristics associated
with ADE reporting; and 2) knowledge, attitudes, and
opinions associated with ADE reporting. Results revealed
that the probability of reporting ADEs increases with
increasing volume of prescriptions and decreases with

A detailed list of steps of the whole project is presented
in Appendix C.

70

		

Akel et al.

CONFLICTS OF INTEREST

increasing patient load. The following attitudes were
identified to be associated with a smaller probability of
reporting: 1) belief that really serious adverse drug events
are well documented by the time a drug is marketed; 2)
belief that it is nearly impossible to determine if a drug is
responsible for a particular adverse event; 3) only reporting
an adverse drug reaction if one is sure that it is related
to the use of a particular drug; and 4) belief that the one
case an individual physician might see cannot contribute
to medical knowledge[25]. In the article “Spontaneous
Reporting Systems: Achieving Less Spontaneity and
More Reporting”[25], time constraint was identified as one
major reason, as the doctors prioritised spending more
time in actual contact with the patients then spending time
on reporting. Liability factor may play a role in stifling
reporting as well. And there is also a preference in the
medical community to publish adverse reactions rather
than to report them.

The authors have nothing to disclose.
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Appendix B

Adverse Reaction (Drug/Product)
Logout
Reporting Form

character size

Eng

A. Information on Adverse Reaction Reporting
Adverse events include both adverse reactions and medication
errors.
An adverse reaction is a harmful and unintended response to a
health product. This includes any undesirable patient effect
suspected to be associated with health product use. Unintended
effect, health product abuse, overdose, interaction, and unusual
lack of therapeutic efficacy are all considered to be reportable
adverse reactions.
A medication error is any preventable event that may (but not
necessarily) cause or lead to inappropriate medication use or
patient harm while the medication is in the control of the
healthcare professional, patient, or consumer.
Medications errors are not reported using this form, but they may
be the cause of adverse reactions as mentioned in section B of that
form.

B. What to Report ?
All suspected adverse reactions should be reported, especially those
that are:
Unexpected, regardless of their severity
Serious, whether expected or not
Reactions to recently marketed health products (≤ 3 years on
the market), regardless of their nature or severity.
A serious adverse reaction is one that requires in-patient
hospitalization or prolongation of existing hospitalization, causes
congenital malformation, results in persistent or significant disability,
is life-threatening or results in death. Adverse reactions that require
significant medical intervention to prevent one of these listed
outcomes are also considered to be serious.

C. Purpose and Scope
In the perspective of medication safety, the Lebanese Order of
Pharmacists (OPL) elaborated an "Adverse reaction (drug/product)
reporting form" in order to report adverse reactions related to any drug
or product administered to a patient in a community or hospital setting
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and has led to an adverse reaction. The aim is to create a standardized
assessment system, reporting objectively any reaction based on a
reliable and reproducible measurement of causality. The present form
has been developed based on the causality assessment system
proposed by the World Health Organization Collaborating Centre for
International Drug Monitoring, the Uppsala Monitoring Centre (WHOUMC), and the Naranjo Probability Scale [1 2]. This tool will allow us
to screen, detect, investigate, analyze and establish any causal
relationship between the drug/product and the adverse event/reaction.
Furthermore, evaluated data will enable us to classify the adverse
event/reaction according to its severity, its probability, and the
pharmaceutical category of drug/product behind its occurrence,
creating a national adverse reaction database of health products, which
will be forwarded, at a later stage, to the Global Pharmacovigilance
Database managed by WHO-UMC. Our ultimate purpose is to support
good decision-making regarding the benefits and risks of treatment
options for patients taking medicines and thus enhancing the key role
of the pharmacist in the practice of medication safety. We appreciate
the time allocated to complete the form. If you have any questions or
concerns,
send
them
to
the
following
email:
medication.safety@opl.org.lb

D. Confidentiality and Protection
Submission of a report does not imply that the reporter, the
institution or the product caused or contributed to the adverse
reaction. Adverse reaction reports are only suspected associations;
[4] they do not imply a definitive causal link.
All obtained data will stay confidential and anonymous;they will be
protected and handled in strict confidence, and will be used for
medication safety reporting and follow up only.

E. Instructions to complete the Adverse Reaction Reporting Form
Use the form to report adverse reactions to Lebanese marketed
health products, including prescription and non-prescription
medications, vitamins and herbal products, electrolytes and serums,
biologically derived products such as vaccines and fractionated
blood products, radiopharmaceuticals and diagnostics, and
cosmetics.
All sections of the form should be filled in as completely as
possible. Each reported adverse reaction requires a separate form
for every patient.
Any follow-up information for an adverse reaction that has already
been reported can be submitted by accessing "review previous
submissions". Selecting the corresponding submission, and adding
a note at the end of the page where indicated. Once done, press
submit.
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F. References
I have read and understood all the above terms & conditions.
I agree
Submit a new form

Review previous submissions
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Appendix C

Appendix C - Medication Safety Plan – Phases
Phase I








Completion End of July 2016

Field assessment of Medication Safety Culture among pharmacists and the population
Pharmacist Form Completed from IT perspective in English
Administrator Completed from IT perspective in English
Manual for Pharmacist Users – Completed In English
Post Manual on the website
Complete the training of 2 DIC pharmacists
Announce Launch by message to pharmacists

Phase II









Completion End of August 2017

Pharmacist Form Completed from IT perspective in French
Administrator Completed from IT perspective in French
Pharmacist Form Completed from IT perspective in Arabic
Administrator Completed from IT perspective in Arabic
Manual for Pharmacist Users – Completed In French
Manual for Pharmacist Users – Completed In Arabic
Post Manual in French and Arabic on the Website
Announce Launch by message to pharmacists

Phase III

Estimated Completion End of December 2017

 Collect Data Entry – Pilot cases
 Analyze the data received – Generate first level recommendation
 Correct the bugs of the reporting system in all three languages
Phase IV
 Establish regular CE sessions related to medication safety (once / 3months – In regions).
Phase IV

Estimated Completion January 2018

 Reset Data
 Start Effective Data Collection with at last 20 reports to submit to UPPSALA
 Initiate Collaboration with Pharmaceutical companies.
Phase V

 Generate Quarterly Report starting June 2018
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